Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.

Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.

Clin Neurol Neurosurg. 2007 May;109(4):350-3. Epub 2007 Feb 20.

PMID:
17307289
2.

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Antonini A, Poewe W.

Lancet Neurol. 2007 Sep;6(9):826-9. Review.

PMID:
17706566
3.

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

N Engl J Med. 2007 Jan 4;356(1):39-46.

4.

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.

Kim JY, Chung EJ, Park SW, Lee WY.

Mov Disord. 2006 Aug;21(8):1261-4.

PMID:
16685692
5.

Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.

Dewey RB 2nd, Reimold SC, O'Suilleabhain PE.

Arch Neurol. 2007 Mar;64(3):377-80.

PMID:
17353380
6.

Dopamine agonists and the risk of cardiac-valve regurgitation.

Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E.

N Engl J Med. 2007 Jan 4;356(1):29-38.

7.

Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.

Simonis G, Fuhrmann JT, Strasser RH.

Mov Disord. 2007 Oct 15;22(13):1936-42.

PMID:
17659636
8.

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

Cardiovasc Ther. 2011 Dec;29(6):404-10. doi: 10.1111/j.1755-5922.2010.00169.x. Epub 2010 Jun 11.

PMID:
20553285
9.

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D.

Lancet. 2004 Apr 10;363(9416):1179-83.

PMID:
15081648
10.

Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.

Růzicka E, Línková H, Penicka M, Ulmanová O, Nováková L, Roth J.

J Neurol. 2007 Nov;254(11):1575-8. Epub 2007 Aug 24.

PMID:
17712588
11.

Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.

Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L.

Arch Neurol. 2007 Dec;64(12):1721-6. Review.

PMID:
18071034
12.

The frequency of cardiac valvular regurgitation in Parkinson's disease.

Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N, Iwama Y, Daida H, Sakai M, Nakayama T, Mizuno Y.

Mov Disord. 2008 May 15;23(7):935-41. doi: 10.1002/mds.22036.

PMID:
18398916
13.

Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.

Dupuy D, Lesbre JP, Gérard P, Andrejak M, Godefroy O.

J Neurol. 2008 Jul;255(7):1045-8. doi: 10.1007/s00415-008-0839-1. Epub 2008 Jun 16.

PMID:
18560792
14.

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.

Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A.

Mov Disord. 2007 Jan 15;22(2):234-8.

PMID:
17094087
15.

[Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].

van Strater AC, Bax JJ, van Hilten JJ, Jukema JW.

Ned Tijdschr Geneeskd. 2005 Apr 16;149(16):891-4. Dutch.

PMID:
15868996
16.

Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.

Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM.

J Clin Endocrinol Metab. 2008 Sep;93(9):3348-56. doi: 10.1210/jc.2007-2658. Epub 2008 Jun 17.

PMID:
18559921
17.

The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.

Ooba N, Yamaguchi T, Kubota K.

Drug Saf. 2011 Apr 1;34(4):329-38. doi: 10.2165/11588230-000000000-00000.

PMID:
21417505
18.

Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.

Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Morikawa K, Nakayama T.

Intern Med. 2011;50(7):687-94. Epub 2011 Apr 1.

19.

[Cardiac valvulopathy and dopamine agonist].

Grandas F.

Neurologia. 2007 Dec;22(10):870-81. Review. Spanish.

PMID:
17671852
20.

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.

Senol MG, Togrol RE.

Neurology. 2007 Jul 3;69(1):117; author reply 117-8. No abstract available.

PMID:
17606893

Supplemental Content

Support Center